https://orcid.org/0000-0003-3105-3589
References
- Cancer Genome Atlas Research N, LeyTJ, MillerC, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi:10.1056/NEJMoa130168923634996
- LevisM. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematol Am Soc Hemat. 2013;2013:220–226. doi:10.1182/asheducation-2013.1.220
- UsukiK, SakuraT, KobayashiY, et al. Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label Phase 1 study. Cancer Sci. 2018;109(10):3235–3244. doi:10.1111/cas.1374930039554
- UenoY, MoriM, KamiyamaY, et al. Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD(+) acute myeloid leukemia. Oncotarget. 2019;10(26):2530–2545. doi:10.18632/oncotarget.2681131069015
- PerlAE, AltmanJK, CortesJ, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol. 2017;18(8):1061–1075. doi:10.1016/S1470-2045(17)30416-328645776
- DhillonS. Gilteritinib: first global approval. Drugs. 2019;79(3):331–339. doi:10.1007/s40265-019-1062-330721452
- Astellas Pharma. XOSPATA (gilteritinib): US prescribing infor- mation. 2018 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211349s000lbl.pdf. Accessed 1224, 2018.
- ClarkJD, GebhartGF, GonderJC, KeelingME, KohnDF Special report: the 1996 guide for the care and use of laboratory animals. ILAR J. 1997;38(1):41–48. doi:10.1093/ilar.38.1.4111528046
- Center for Drug Evaluation and Research of the U.S. Department of Health and Human Services Food and Drug Administration, Guidance for industry; Bioanalytical method validation. 2018 Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064964.htm. Accessed 82, 2018.
- ZhouX, PantS, NemunaitisJ, et al. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies. Invest New Drugs. 2018;36(2):248–258. doi:10.1007/s10637-017-0499-z28852909
- BarbourAM, PunwaniN, EpsteinN, et al. Effect of Itraconazole or rifampin on itacitinib pharmacokinetics when administered orally in healthy subjects. J Clin Pharmacol. 2019;59(12):1641–1647. doi:10.1002/jcph.148431282592
- DaiD, YangH, NabhanS, et al. Effect of itraconazole, food, and ethnic origin on the pharmacokinetics of ivosidenib in healthy subjects. Eur J Clin Pharmacol. 2019;75(8):1099–1108. doi:10.1007/s00228-019-02673-631011758
- KaukonenKM, OlkkolaKT, NeuvonenPJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol. 1998;53(6):445–449. doi:10.1007/s0022800504059551703
- YangJ, AtkinsWM, IsoherranenN, PaineMF, ThummelKE. Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam. Clin Pharmacol Ther. 2012;91(3):442–449. doi:10.1038/clpt.2011.17822048224
- MalhiV, ColburnD, WilliamsSJ, et al. A clinical drug-drug interaction study to evaluate the effect of a proton-pump inhibitor, a combined P-glycoprotein/cytochrome 450 enzyme (CYP)3A4 inhibitor, and a CYP2C9 inhibitor on the pharmacokinetics of vismodegib. Cancer Chemother Pharmacol. 2016;78(1):41–49. doi:10.1007/s00280-016-3020-z27154174